New method to measure cancer-related protein kinases in cells and tissues
Official title: Activity-based Sensor Peptides for Direct, High-throughput, and Kinetic Quantitation of Oncogenic Protein Kinases in Unfractionated Cell and Tissue Samples
Funded at Assayquant Technologies, INC. · NIH-11008528 · Data updated 2026-11-12
This study is working on a new way to measure how certain proteins, important for cell health and often involved in cancer, are working in real-time, which could help scientists find better treatments for cancer and related diseases.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Assayquant Technologies, INC. NIH-funded |
| Lab location | 1 site (Marlborough, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,093,104 |
| NIH project number | 1R44CA295425-01 |
| Project ID | NIH-11008528 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers or diseases associated with abnormal protein kinase activity.
✕Less likely to help
Patients with conditions unrelated to protein kinases or those not currently undergoing treatment for cancer may not benefit from this research.
What this research studies
This research focuses on developing a novel assay platform to accurately measure the activity of protein kinases, which are crucial for cell function and are often implicated in cancer. The approach utilizes specially designed sensor peptides that can detect phosphorylation events in real-time, providing a more efficient way to evaluate kinase activity in various biological samples. By improving the methods used to study these enzymes, the research aims to enhance drug discovery processes and ultimately lead to better treatment options for patients with cancer and other diseases linked to kinase dysfunction.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for cancer by improving the drug development process targeting protein kinases.
How similar studies have gone: Other research has shown promise in developing similar assay technologies, indicating potential for success in this novel approach.
Where this research is happening
-
Assayquant Technologies, INC.
Marlborough, United States Active
Researchers
- Principal investigator: Schaefer, Erik Michael — Assayquant Technologies, INC.
- Study coordinator: Schaefer, Erik Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.